New pharmacological approaches in infants with hypoxic-ischemic encephalopathy

Current Pharmaceutical Design

Volumn 18, Issue 21, 2012, Pages 3086-3100

  Buonocore, Giuseppe ^a   Perrone, Serafina ^a   Turrisi, Giovanni ^a   Kramer, Boris W ^b   Balduini, Walter ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF URBINO   (Italy)

Author keywords

Birth asphyxia; Brain injury; Hypoxic ischemic encephalopathy; Neuroprotection; Newborn infant; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CANNABINOID; CASPASE 3; CATALASE; DEFEROXAMINE; FAS ANTIGEN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAGNESIUM; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; UNINDEXED DRUG; XENON;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BOLD SIGNAL; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN INJURY; CALCIUM CELL LEVEL; CELL DEATH; CEREBRAL PALSY; CEREBRAL REVASCULARIZATION; CHORIOAMNIONITIS; CLINICAL ASSESSMENT; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA FRAGMENTATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVATION; FETUS HEART RATE; HOSPITAL READMISSION; HUMAN; HYPOTHERMIA; HYPOXEMIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFANT; LIPID PEROXIDATION; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; META ANALYSIS; MICROGLIA; MITOCHONDRION; NERVE REGENERATION; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PREMATURITY; PRIORITY JOURNAL; REPERFUSION INJURY; RISK FACTOR; SEX DIFFERENCE; STEADY STATE; TREATMENT DURATION; UMBILICAL CORD BLOOD; WHITE MATTER;

EID: 84862595577     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023086     Document Type: Article

References (196)

1. Kumar S, Paterson-Brown S. Obstetric aspects of hypoxic ischemic encephalopathy. Early Hum Dev 2010; 86: 339-44.
2. Lai MC, Yang SN. Perinatal hypoxic ischemic encephalopathy. J Biomed Biotechnol 2011; 2011: 609813.
3. Nelson KB, Leviton A. How much of neonatal encephalopathy is due to birth asphyxia? Am J Dis Child 1991; 145: 1325-31.
4. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 1976; 33: 696-705.
5. Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE. A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol 2008; 199: 587-95.
6. American College of Obstetricians and Gynecologists, Women's Health Care Physicians ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2004; 103: 203-16.
7. Volpe JJ. In: Volpe JJ, Ed. Neurology of the newborn. Philadelphia: Saunders Elsevier 2008; pp. 347-99.
8. Delivoria-Papadopoulos M, Ashraf QM, Mishra OP. Effect of hypoxia on expression of apoptotic proteins in nuclear, mitochondrial and cytosolic fractions of the cerebral cortex of newborn piglets the role of nuclear Ca++-influx. Neurochem Res 2008; 33: 1196-204.
9. Mishra OP, Zubrow AB, Ashraf QM, Delivoria-Papadopoulos M. Effect of nitric oxide synthase inhibition during post-hypoxic reoxygenation on Bax and Bcl-2 protein expression and DNA fragmentation in neuronal nuclei of newborn piglets. Brain Res 2006; 1101: 20-8.
10. Arundine M, Tymianski M. Molecular mechanisms of calciumdependent neurodegeneration in excitotoxicity. Cell Calcium 2003; 34: 325-37.
11. Johnston MV. Excitotoxicity in perinatal brain injury. Brain Pathol 2005; 15: 234-40.
12. Brazel CY, Nuñez JL, Yang Z, Levison SW. Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 2005; 131: 55-65.
13. Herlitze S, Raditsch M, Ruppersberg JP, et al. Argiotoxin detects molecular differences in AMPA receptor channels. Neuron 1993; 10: 1131-40.
14. Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. Lancet Neurol 2011; 10: 372-82.
15. Hilton GD, Nunez JL, Bambrick L, Thompson SM, McCarthy MM. Glutamate-mediated excitotoxicity in neonatal hippocampal neurons is mediated by mGluR-induced release of Ca++ from intracellular stores and is prevented by estradiol. Eur J Neurosci 2006; 24: 3008-16.
16. Babu GN, Bawari M, Ali MM. Lipid peroxidation potential and antioxidant status of circumventricular organs of rat brain following neonatal monosodium glutamate. Neurotoxicology 1994; 15: 773-7.
17. Carden DL, Granger DN. Pathophysiology of ischaemiareperfusion injury. J Pathol 2000; 190: 255-66.
18. -.), superoxide dismutases, and related matters. J Biol Chem 1997; 272: 18515-7.
19. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30: 1191-21.
20. Buonocore G, Groenendaal F. Anti-oxidant strategies. Semin Fetal Neonatal Med 2007; 12: 287-95.
21. Ferriero DM. Oxidant mechanisms in neonatal hypoxia-ischemia. Dev Neurosci 2001; 23: 198-202.
22. Schaller B. Prospects for the future: the role of free radicals in the treatment of stroke. Free Radic Biol Med 2005; 38: 411-25.
23. Khan JY, Black SM. Developmental changes in murine brain antioxidant enzymes. Pediatr Res 2003; 1: 77-82.
24. McQuillen PS, Ferriero DM. Selective vulnerability in the developing central nervous system. Pediatr Neurol 2004; 30: 227-35.
25. Iida K, Takashima S, Ueda K. Immunohistochemical study of myelination and oligodendrocyte in infants with periventricular leukomalacia. Pediatr Neurol 1995; 13: 296-304.
26. Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia 1996; 17: 83-93.
27. Buonocore G, Zani S, Sargentini I, Gioia D, Signorini C, Bracci R. Hypoxia-induced free iron release in the red cells of newborn infants. Acta Paediatr 1998; 87: 77-81.
28. Ciccoli L, Rossi V, Leoncini S, et al. Iron release in erythrocytes and plasma non protein-bound iron in hypoxic and non hypoxic newborns. Free Rad Res 2003; 37: 51-8.
29. Fiskum G, Rosenthal RE, Vereczki V, et al. Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress. J Bioenerg Biomembr 2004; 36: 347-52.
30. Mishra OP, Mishra R, Ashraf QM, Delivoria-Papadopoulos M. Nitric oxide-mediated mechanism of neuronal nitric oxide synthase and inducible nitric oxide synthase expression during hypoxia in the cerebral cortex of newborn piglets. Neuroscience 2003; 140: 857-63.
31. Felderhoff-Mueser U, Bittigau P, Sifringer M, et al. Oxygen causes cell death in the developing brain. Neurobiol Dis 2004; 17: 273-82.
32. Mishra OP, Randis T, Ashraf QM, Delivoria-Papadopoulos M. Hypoxia-induced Bax and Bcl-2 protein expression, caspase-9 activation, DNA fragmentation, and lipid peroxidation in mitochondria of the cerebral cortex of newborn piglets: the role of nitric oxide. Neuroscience 2006; 141: 1339-49.
33. Mehmet H, Yue X, Squier MV, et al. Increased apoptosis in the cingulate sulcus of newborn piglets following transient hypoxia ischaemia is related to the degree of high energy phosphate depletion during the insult. Neurosi Lett 1994; 181: 121-5.
34. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
35. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA. Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur J Neurosci 2004; 20: 1713-26.
36. Zhivotovsky B, Orrenius S, Brustugun OT, Døskeland SO. Injected cytochrome c induces apoptosis. Nature 1991; 391: 449-50.
37. Genestra M. Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal 2007; 19: 1807-19.
38. Mishra OP, Delivoria-Papadopoulos M. Nitric oxide-mediated Ca++-influx in neuronal nuclei and cortical synaptosomes of normoxic and hypoxic newborn piglets. Neurosci Lett 2002; 318: 93-7.
39. Berridge MJ, Bootman MD, Lipp P. Calcium-a life and death signal. Nature 1998; 395: 645-8.
40. Ota K, Yakovlev AG, Itaya A, Kameoka M, Tanaka Y, Yoshihara K. Alteration of apoptotic protease-activating factor-1 (APAF-1)-dependent apoptotic pathway during development of rat brain and liver. J Biochem 2002; 131: 131-2.
41. Northington FJ, Chavez-Valdes R, Martin L. Neuronal cell death in neonatal hypoxia-ischemia. Ann Neurol 2011; 69: 743-58
42. Mronga T, Stahnke T, Goldbaum O, Richter-Landsberg C. Mitochondrial pathway is involved in hydrogen-peroxide-induced apoptotic cell death of oligodendrocytes. Glia 2004; 46: 446-55.
43. Rosenberg PA. Hyperoxia causes maturation-dependent cell death in the developing white matter. J Neurosci 2008; 28: 1236-45.
44. Pourova J, Kottova M, Voprsalova M, Pour M. Reactive oxygen and nitrogen species in normal physiological processes. Acta Physiol 2010; 198: 15-35.
45. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009; 7: 97-104.
46. Wang X, Hagberg H, Nie C, Zhu C, Ikeda T, Mallard C. Dual role of intrauterine immune challenge on neonatal and adult brain vulnerability to hypoxia-ischemia. J Neuropathol Exp Neurol 2007; 66: 552-61.
47. Wang X, Hagberg H, Zhu C, Jacobsson B, Mallard C. Effects of intrauterine inflammation on the developing mouse brain. Brain Res 2007; 1144: 180-5.
48. Rousset CI, Chalon S, Cantagrel S, et al. Maternal exposure to LPS induces hypomyelination in the internal capsule and programmed cell death in the deep gray matter in newborn rats. Pediatr Res 2006; 59: 428-33.
49. Garnier Y, Coumans AB, Jensen A, Hasaart TH, Berger R. Infection-related perinatal brain injury: the pathogenic role of impaired fetal cardiovascular control. J Soc Gynecol Investig 2003; 10: 450-9.
50. Møller K, Strauss GI, Qvist J, et al. Cerebral blood flow and oxidative metabolism during human endotoxemia. J Cereb Blood Flow Metab 2002; 22: 1262-70.
51. Hagberg H, Mallard C. Effect of inflammation on central nervous system development and vulnerability. Curr Opin Neurol 2005; 18: 117-23.
52. Bell MJ, Hallenbeck JM, Gallo V. Determining the fetal inflammatory response in an experimental model of intrauterine inflammation in rats. Pediatr Res 2004; 56: 541-6.
53. Barger SW, Goodwin ME Segovia KN, McClure M, Maravec M, et al. Arrested oligodendrocyte lineage maturation in chronic perinatal white matter. Ann Neurol 2008; 63: 520-30.
54. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med. 1980; 93: 480-9
55. Halliwell B. Phagocyte-derived reactive species: salvation or suicide? Trends Biochem Sci 2006; 31: 509-15.
56. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
57. Griendling KK, Sorescu D, Lassegue B, Uschio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-83.
58. Back SA, Craig A, Kayton RJ, et al. Hypoxia-ischemia preferentially triggers glutamate depletion from oligodendroglia and axons in perinatal cerebral white matter. J Cereb Blood Flow Metab 2007; 27: 334-47.
59. Matute C, Alberdi E, Domercq M, et al. Excitotoxic damage to white matter. J Anat 2007; 210: 693-702.
60. Matute C, Domercq M, Sánchez-Gómez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006; 53: 212-24.
61. Shankaran S. Neonatal encephalopathy: treatment with hypothermia. J Neurotrauma. 2009; 26: 437-43.
62. Ramaswamy V, Horton J, Vandermeer B, Buscemi N, Miller S, Yager J. Systematic review of biomarkers of brain injury in term neonatal encephalopathy. Pediatr Neurol 2009; 40: 215-26.
63. Low JA, Lindasay BG, Derrick EJ. Threshold of metabolic acidosis asssociated with newborn complications. Am J Obstet Gynecol. 1997; 177: 1391-4.
64. Hagelin A, Leyon J. The effect of labor on the acid-base status of the newborn. Acta Obstet Gynecol Scand 1998; 158: 356-61.
65. Meyer RS. Four patterns of perinatal brain damage and their conditiones of occurrence in primates. Adv Neurol 1975; 10: 223-34.
66. Boog G. Microdosage rapide des lactates au sang du cordon et au scalp foetal. Gynécol Obstét Fertil 2004; 32: 241-4.
67. Da Silva S, Hennerbert N, Denis R, Wayenberg JL. Clinical value of a single postnatal lactate measurement after intrapartum asphyxia. Acta Paediatr 2000; 89: 320-2.
68. Perrone S, Tataranno ML, Negro, et al. Early identification of the risk for free radical related diseases in preterm newborns. Early Hum Dev 2010; 86: 241-4.
69. Buonocore G, Perrone S, Longini M, Paffetti P, Gatti MG, Bracci R. Non protein bound iron as predictive marker of neonatal brain damage. Brain 2003; 126: 1-7.
70. Signorini C, Perrone S, Sgherri C, et al. Plasma esterified F2-isoprostanes and oxidative stress in newborns: role of nonproteinbound iron. Pediatr Res. 2008; 63:287-91
71. Nyska A, Kohen R. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002; 30: 620-30.
72. Milne GL, Yin H, Brooks JD, et al. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007; 433: 113-26.
73. nd. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA 2002; 99: 16713-18.
74. nd. Measurement of products of docosahexaenoic acid peroxidation, neuroprostanes, and neurofurans. Methods Enzymol 2007; 433: 127-43.
75. Musiek ES, Brooks JD, Joo M, et al. Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem 2008; 283: 19927-35.
76. Song WL, Lawson JA, Reilly D, et al. Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem. 2008; 283: 6-16.
77. Dammann O, Leviton A. Biomarker epidemiology of cerebral palsy. Ann Neurol 2004; 55: 158-61.
78. Kotiranta-Ainamo A, Rautonen J, Rautonen N. Imbalanced cytokine secretion in newborn. Biol Neonate 2004; 85: 55-60.
79. Jun JK, Yoon BH, Romero R, et al. Interleukin 6 determinations in cervical fluid have diagnostic and prognostic value in preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 183: 868-73.
80. Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA 2000; 284: 1417-24.
81. Impey L, Greenwood C, MacQuillan K, Reynolds M, Sheil O. Fever in labour and neonatal encephalopathy: a prospective cohort study. Br J Obstet Gynecol 2001; 108: 594-7.
82. Kaukola T, Satyaraj E, Patel DD. Cerebral palsy is characterized by protein mediators in cord serum. Ann Neurol 2004; 55: 186-94.
83. Minagawa K, Tsuji Y, Ueda H, et al. Possible correlation between high levels of IL-18 in the cord blood of preterm infants and neonatal development of periventricular leukomalacia and cerebral palsy. Cytokine 2002; 17: 164-70.
84. Lorenzi S, De Pasquale G, Segal AZ, Beal MF. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 2003; 34: 37-8.
85. Leonardo CC, Pennypacker KR. Neuroinflammation and MMPs: potential therapeutic targets in neonatal hypoxic-ischemic injury. J Neuroinflammation 2009; 15: 6-13.
86. Sunugawa S, Ichiyama T, Honda R, Fukunaga S, Maeba S, Furukawa S. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in perinatal asphyxia. Brain Dev 2009; 31: 588-93.
87. Blennow M, Savman K, Ilves P, Thoresen M, Rosengren L. Brainspecific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr 2001; 90: 1171-5.
88. Jenkin G, Ward J, Hooper S, O'Connor A, De Kretser D, Wallace E. Feto-placental hypoxemia regulates the release of fetal activin A and prostaglandin E (2). Endocrinology 2001; 142: 963-6.
89. Florio P, Perrone S, Luisi S, et al. Activin a plasma levels at birth: an index of fetal hypoxia in preterm newborn. Pediatr Res 2003; 54: 696-700.
90. Florio P, Perrone S, Luisi S, et al. Increased plasma concentrations of activin a predict intraventricular hemorrhage in preterm newborns. Clin Chem 2006; 52, 1516-21.
91. Miller SP, Ferriero D. From selective vulnerability to connectivity: insights from newborn brain injury. Trend in Neurosci 2009; 32: 496-505.
92. Sheldon RA, Sedik C, Ferriero DM. Strain-related brain injury in neonatal mice subjected to hypoxia-ischemia. Brain Res 1998; 810: 114-22.
93. Nuñez JL, McCarthy MM. Sex differences and hormonal effects in a model of preterm infant brain injury. Ann N Y Acad Sci 2003; 1008: 281-4.
94. Ment LR, Hirtz D,. Hüppi PS. Imaging biomarkers of outcome in the developing preterm brain. Lancet Neurol 2009; 8: 1042-55.
95. El Ayouty M, Abdel-Hady H, El Mogy S, et al. Relationship between electroencephalography and magnetic resonance imaging findings after hypoxic-ischemic encephalopathy at term. Am J Perinatol 2007; 24: 467-73.
96. Rutherford M, Srinivasan L, Dyet L, et al. Magnetic resonance imaging in perinatal brain injury: clinical presentation, lesions and outcome. Pediatr Radiol 2006; 36: 582-92.
97. Barkovich AJ, Miller SP, Bartha A, et al. MR imaging, MR spectroscopy, and diffusion tensor imaging of sequential studies in neonates with encephalopathy. AJNR Am J Neuroradiol 2006; 27: 533-47.
98. Mukherjee P, McKinstry RC. Diffusion tensor imaging and tractography of human brain development. Neuroimag Clin N Am 2006; 16: 19-43.
99. Miller SP, Ramaswamy V, Michelson D, et al. Patterns of brain injury in term neonatal encephalopathy. J Pediatr 2005; 146: 453-60.
100. Miller SP, Newton N, FerrieroDM, et al. Predictors of 30-month outcome after perinatal depression: role of proton MRS and socioeconomic factors. Pediatr Res 2002; 52: 71-7.
101. Dubois J, Benders M, Cachia A, et al. Mapping the early cortical folding process in the preterm newborn brain. Cereb Cortex 2008; 18: 1444-5473.
102. Inder TE, Hüppi PS, Zientara GP, et al. The postmigrational development of polymicrogyria documented by magnetic resonance imaging from 31 weeks' postconceptional age. Ann Neurol 1999; 45: 798-801.
103. Ramenghi LA, Fumagalli M, Righini A, et al. Magnetic resonance imaging assessment of brain maturation in preterm neonates with punctate white matter lesions. Neuroradiology 2007; 49: 161-67.
104. Sirén AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6: 108-27.
105. Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010; 125: e1135-42.
106. McPherson RJ, Juul SE. Erythropoietin for infants with hypoxicischemic encephalopathy. Curr. Opin. Pediatr 2010; 22: 139-145.
107. Yis U, Kurul SH, Kumral A, et al. Effect of erythropoietin on oxygen-induced brain injury in the newborn rat. Neurosci Lett 2008; 448: 245-9.
108. Wang Y, Liu W, Cao Y, Mengn Y. Focused Conference Group: P01-Clinical pharmacology in the emerging countries study on protection effect of erythropoietin on newborn rats with hypoxicischemic brain damage. Basic Clin Pharmacol Toxicol 2010; 107: 651-4.
109. Spandou E, Soubasi V, Papoutsopoulou S, et al. Erythropoietin prevents hypoxia/ischemia-induced DNA fragmentation in an experimental model of perinatal asphyxia. Neurosci Lett 2004; 366: 24-8.
110. Wei L, Han BH, Li Y, Keogh CL, Holtzman, DM, Yu SP. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J Pharmacol Exp Ther 2006; 317: 109-16.
111. Kumral A, Genc S, Ozer E, et al. Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxicischemic brain injury. Biol Neonate 2006; 89: 205-10.
112. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 2005; 36: 1672-78.
113. Juul SE, Beyer RP, Bammler TK, McPherson RJ, Wilkerson J, Farin FM. Microarray analysis of high-dose recombinant erythropoietin treatment of uni-lateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009; 65: 485-92.
114. Shen Y, Yu HM, Yuan TM, Gu WZ, Wu YD. Erythropoietin attenuates white matter damage, proinflammatory cytokine and chemokine induction in developing rat brain after intra-uterine infection. Neuropathology 2009; 29: 528-35.
115. Rees S, Hale N, De Matteo R, et al. Erythropoietin is neuroprotective in a preterm ovine model of endotoxin-induced brain injury. J Neuropathol Exp Neurol 2010; 69: 306-19.
116. Wojtowicz T, Mozrzymas JW. Erythropoietin affects GABAergic transmis-sion in hippocampal neurons in vitro. Cell Mol Biol Lett 2008; 13: 649-55.
117. Zacharias R, Schmidt M, Kny J, et al. Dose-dependent effects of erythropoietin in propofol anesthetized neonatal rats. Brain Res 2010; 1343: 14-9.
118. Kumral A, Tugyan K, Gonenc S, et al. Protective effects of erythropoietin against ethanol-induced apoptotic neurodegenaration and oxidative stress in the devel-oping C57BL/6 mouse brain. Brain Res Dev Brain Res 2005; 160: 146-56.
119. Ong J, Plane JM, Parent JM, Silverstein FS. Hypoxic-ischemic injury stim-ulates subventricular zone proliferation and neurogenesis in the neonatal rat. Pediatr Res 2005; 58: 600-6.
120. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin pro-motes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007; 38: 2795-803.
121. Wang X, Zhu C, Gerwien JG, et al. The non erythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004; 91: 900-10.
122. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-43.
123. Osredkar D, Sall JW, Bickler PE, Ferriero DM. Erythropoietin promotes hippocampal neurogenesis in in vitro models of neonatal stroke. Neurobiol Dis 2010; 38: 259-65.
124. Gonzalez FF, McQuillen P, Mu D, et al. Erythropoietin enhances long-term neuroprotection and neuroge-nesis in neonatal stroke. Dev Neurosci 2007; 29: 321-30.
125. Lee SM, Nguyen TH, Park MH, et al. EPO receptor-mediated ERK kinase and NF-kappaB activa-tion in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun 2004; 320: 1087-95.
126. Iwai M, Stetler RA, Xing J, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythro-poietin after neonatal hypoxic/ischemic brain injury. Stroke 2010; 41: 1032-7.
127. Berkingali N, Warnecke A, Gomes P, et al. Neurite outgrowth on cultured spiral ganglion neurons induced by ery-thropoietin. Hear Res 2008; 243: 121-6.
128. Mizuno K, Hida H, Masuda T, Nishino H, Togari H. Pretreatment with low doses of erythropoietin ameliorates brain damage in periventricular leukomalacia by targeting late oligodendrocyte progenitors: a rat model. Neonatology 2008; 94: 255-66.
129. Keller M, Yang J, Griesmaier E, et al. Erythropoietin is neuroprotective against NMDA-receptor-mediated excitotoxic brain injury in newborn mice. Neurobiol Dis 2006; 24: 357-66.
130. Mazur M, Miller RH, Robinson S. Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxicischemic injury. J Neurosurg Pediatr 2010; 6: 206-21.
131. Marion D, Bullock MR. Current and future role of therapeutic hypothermia. J Neurotrauma 2009; 26: 455-67.
132. Fan X, van Bel F. Pharmacological neuroprotection after perinatal asphyxia. J Maternal Fetal Neonatal Med 2010; 23: 17-9.
133. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009; 124: e218-26.
134. Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010; 125: e1135-42.
135. Shah N, Jadav P, Jean-Baptiste D, Weedon J, Cohen LM, Kim MR. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol 2010; 27: 67-71.
136. Chen JM, Jeng MJ, Chiu SY, et al. Conditions associated with hypertension in a high-risk premature infant. J Chin Med Assoc 2008; 71: 485-90.
137. Haiden N, Cardona F, Schwindt J, et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin ther-apy for treatment of anaemia of prematurity. Thromb Haemost 2005; 93: 118-23.
138. Strunk T, Hartel C, Schultz C. Does erythropoietin protect the preterm brain? Arch Dis Child Fetal Neonatal Ed 2004; 89: F364-6.
139. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-43.
140. Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. TOBY Study Group. N Engl J Med 2009; 361: 1349-58.
141. Carroll M, Beek O. Protection against hippocampal CA cell loss by post-ischemic hypothermia is dependent on delay of initiation and duration. Metabolic Brain Disease 1992; 1: 45-50.
142. Perrone S, Szabò M, Bellieni CV, et al. Whole body hypothermia and oxidative stress in babies with hypoxic-ischemic brain injury. Pediatr Neurol 2010; 43: 236-40.
143. Azzopardi D, Edwards AD. Hypothermia. Semin Fetal Neonatal Med 2007; 12: 303-10.
144. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. Pediatrics 2002; 110: 377-85.
145. Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants after perinatal asphyxia: a safety study. Pediatrics 1998; 102: 885-92.
146. Azzopardi D, Robertson NJ, Cowan FM, Rutherford MA, Rampling M, Edwards AD. Pilot study of treatment with whole body hypothermia for neonatal encephalopathy. Pediatrics 2000; 106: 684-94.
147. Edwards AD, Brocklehurst P, Gunn AJ, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 2010; 340: c363.
148. Perlman M, Shah PS. Hypoxic ischemic encephalopathy: challenge in outcome and prediction. J of Pediatr 2011; 158: e51-4.
149. Pimentel-Coelho PM, Mendez-Otero R. Cell therapy for neonatal hypoxic-ischemic encephalopathy. Stem Cells Dev. 2010 Mar;19: 299-310.
150. Jeong SW, Chu K, Jung KH, Kim SU, Kim M, Roh JK. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke. 2003; 34: 2258-63.
151. Lee IS, Jung K, Kim M, Park KI. Neural stem cells: properties and therapeutic potentials for hypoxic-ischemic brain injury in newborn infants. Pediatr Int. 2010; 52:855-65.
152. Zhang H, Huang Z, Xu Y, Zhang S. Differentiation and neurological benefit of the mesenchymal stem cells transplanted into the rat brain following intracerebral hemorrhage. Neurol Res. 2006;28:104-12.
153. Xia G, Hong X, Chen X, Lan F, Zhang G, Liao L. Intracerebral transplantation of mesenchymal stem cells derived from human umbilical cord blood alleviates hypoxic ischemic brain injury in rat neonates. J Perinat Med. 2010;38:215-21.
154. Kaandorp JJ, Benders MJ, Rademaker CM, et al. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study. BMC Pregnancy Childbirth 2010; 10: 8.
155. Benders MJ, Bos AF, Rademaker CM, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fetal Neonatal Ed 2006; 91: F163-5.
156. Kelen D, Robertson NJ. Experimental treatments for hypoxic ischaemic encephalopathy. Early Hum Dev 2010; 86: 369-77.
157. van den Tweel ER, van Bel F, Kavelaars A, et al. Long-term neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats. J Cereb Blood Flow Metab 2005; 25: 67-74.
158. Nijboer CH, Groenendaal F, Kavelaars A, Hagberg HH, van Bel F, Heijnen CJ. Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway. J Cereb Blood Flow Metab 2007; 27: 282-92.
159. Peeters-Scholte C, van den Tweel E, Ioroi T, et al. Pharmacological interventions in the newborn piglet in the first 24 h after hypoxiaischemia. A hemodynamic and electrophysiological perspective. Exp Brain Res 2002; 147: 200-8.
160. Mu D, Chang YS, Vexler ZS, Ferriero DM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol 2005; 195: 407-15.
161. deLemos RA, Roberts RJ, Coalson JJ, deLemos JA, Null DM Jr, Gerstmann DR. Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. Am J Dis Child 1990; 144: 915-9.
162. Cetinkaya M, Alkan T, Ozyener F, Kafa IM, Kurt MA, Koksal N. Possible neuroprotective effects of magnesium sulfate and melatonin as both pre-and post-treatment in a neonatal hypoxicischemic rat model. Neonatology 2010; 99: 302-10.
163. Westermaier T, Zausinger S, Baethmann A, Schmid-Elsaesser R. Dose finding study of intravenous magnesium sulphate in transient focal cerebral ischemia in rats. Acta Neurochir 2005; 147: 525-32.
164. Dworschak M. Pharmacologic neuroprotection--is xenon the light at the end of the tunnel? Crit Care Med 2008; 36: 2477-9.
165. David NH, Haelewyn B, Rouillon C, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J 2008; 22: 1275-86.
166. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004; 65: 443-52.
167. Thoresen M, Hobbs CE, Wood T, Chakkarapani E, Dingley J. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab 2009; 29: 707-14.
168. Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke 2008; 39: 1307-13.
169. Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides shortterm neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37: 501-6
170. Dorottya K, Robertson NJ. Experimental treatments for hypoxic ischaemic encephalopathy. Early Human Development 2010; 86: 369-77.
171. Khan M, Sekhon B, Jatana M, et al. Administration of Nacetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res 2004; 76: 519-27.
172. Jatana M, Singh I, Singh AK, Jenkins D. Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2006; 59: 684-9.
173. Wang X, Svedin P, Nie C, et al. N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol 2007; 61: 263-71.
174. Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. The Lancet Neurology 2011; 10: 372-82.
175. Ahola T, Lapatto R, Raivio KO, et al. N-Acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 2003; 143: 713-9.
176. Alvarez FJ, Lafuente H, Rey-Santano MC, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxicischemic newborn piglets. Pediatr Res 2008; 64: 653-8.
177. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emergency theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 2001; 23: 1-11.
178. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Current Neuropharmacology 2010; 8: 228-42.
179. Reiter RJ, Tan DX, Qi W, Manchester LC, Karbownik M, Calvo JR. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biological Signals and Receptors 2000; 9: 160-71.
180. Petri ES, Ajao MS, Olaleye O, Ihunwo AO. Effect of melatonin on neuronal nitric oxide synthase expressing cells in the brain following global cerebral ischemia. Journal of Animal and Veterinary Advances 2011; 10: 395-400.
181. Mohan N, Sadeghi K, Reiter RJ, Meltz ML. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995; 37: 1063-70.
182. Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006; 108: 518-24.
183. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicological Sciences 1999; 50: 271-9.
184. Welin AK, Svedin P, Lapatto R, et al. Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatric Research 2007; 61: 153-8.
185. Olivier P, Fontaine RH, Loron G, et al. Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS One 2009; 4: e7128.
186. Carloni S, Perrone S, Buonocore G, Longini M, Proietti F, Balduini W. Melatonin protects from the long-term consequences of a neonatal hypoxic-ischemic brain injury in rats. J Pineal Res 2008; 44: 157-64.
187. Signorini C, Ciccoli L, Leoncini S, et al. Free iron, total Fisoprostanes and total F-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin. J Pineal Res 2009; 46: 148-54.
188. Cimino M, Balduini W, Carloni S, et al. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology 2005; 26: 929-33.
189. Prinz V, Endres M. Statins and stroke: Prevention and beyond. Current Opinion in Neurology 2011; 24: 75-80.
190. Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke 2001; 32: 2185-91.
191. Balduini W, Mazzoni E, Carloni S, et al. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxicischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 2003; 34: 2007-12.
192. Carloni S, Girelli S, Buonocore G, Longini M, Balduini W. Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation. Exp Neurol 2009; 220: 82-9.
193. Li A, Lv S, Yu Z, et al. Simvastatin attenuates hypomyelination induced by hypoxia-ischemia in neonatal rats. Neurological Research 2010; 32: 945-52.
194. Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci 2004; 27: 283-9.
195. Carloni S, Mazzoni E, Cimino M, et al. Simvastatin reduces caspase-3 activation inflammatory markers induced by hypoxiaischemia in the newborn rat. Neurobiol Dis 2006; 21: 119-26.
196. Hong H, Zeng JS, Kreulen DL, Kaufman DI, Chen AF. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. American Journal of Physiology-Heart and Circulatory Physiology 2006; 291: H2210-15.